A Message from Veracyte’s CEO About COVID-19     Learn More
A Message from Veracyte’s CEO About COVID-19     Learn More
Skip to content
OVERVIEW
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.

OVERVIEW

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Second Quarter 2020 Financial Results
Revenue of $20.7 Million and Genomic Testing Volume of 5,379 Company Advances Pipeline and Global Expansion Strategy Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 30, 2020-- Veracyte, Inc . (Nasdaq: VCYT) today announced financial results for
View HTML
Toggle Summary Veracyte Announces Data Published in AJRCCM Showing That the Envisia Genomic Classifier Improves Physicians’ Ability to Diagnose IPF Without Surgery
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 30, 2020-- Veracyte, Inc . (Nasdaq: VCYT) today announced new study results showing that use of the Envisia ® Genomic Classifier improves physicians’ ability to diagnose idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases
View HTML

Events

There are currently no events to display.

Presentations

Title Documents

Corporate Presentation June 2020